Wednesday, September 4, 2013
• Esperion Therapeutics Inc., of Plymouth, Mich., reported top-line results from a Phase IIa study of ETC-1002 when added to statin therapy in patients with elevated levels of low-density lipoprotein cholesterol (LDL-C), with data showing that oral, once-daily ETC-1002 achieved incremental LDL-C lowering of 22 percent at eight weeks, compared with 0 percent in the placebo group, when added to 10 mg of atorvastatin (p < 0.0001).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.